Immune Cell Networks Uncover Candidate Biomarkers of Melanoma Immunotherapy Response
The therapeutic activation of antitumour immunity by immune checkpoint inhibitors (ICIs) is a significant advance in cancer medicine, not least due to the prospect of long-term remission. However, many patients are unresponsive to ICI therapy and may experience serious side effects; companion biomar...
Main Authors: | Duong H. T. Vo, Gerard McGleave, Ian M. Overton |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2022-06-01
|
Series: | Journal of Personalized Medicine |
Subjects: | |
Online Access: | https://www.mdpi.com/2075-4426/12/6/958 |
Similar Items
-
Soluble immune checkpoints and T-cell subsets in blood as biomarkers for resistance to immunotherapy in melanoma patients
by: Devayani Machiraju, et al.
Published: (2021-01-01) -
Editorial of special focus on melanoma immunotherapy
by: Ernesto Rossi
Published: (2022-05-01) -
Immune Response in Melanoma: A Basis to Understand the Role of Immunotherapy with Immune Checkpoint Inhibitors
by: Eugénia Matos Pires, et al.
Published: (2018-04-01) -
The age of enlightenment in melanoma immunotherapy
by: Mark R. Albertini
Published: (2018-08-01) -
Current Status and Prospects of Immunotherapy for Gynecologic Melanoma
by: Mayuka Anko, et al.
Published: (2021-05-01)